Open AccessPatients with multiple myeloma or monoclonal gammopathy of undetermined significance—diagnosis, treatment, and follow-up
Author(s) -
Vanessa Piechotta,
Nicole Skoetz,
Monika Engelhardt,
Hermann Einsele,
Hartmut Goldschmidt,
Christof Scheid
Publication year - 2022
Publication title -
deutsches ärzteblatt international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.436
H-Index - 60
ISSN - 1866-0452
DOI - 10.3238/arztebl.m2022.0149
Subject(s) - medicine , guideline , multiple myeloma , monoclonal gammopathy of undetermined significance , plasma cell neoplasm , medline , randomized controlled trial , intensive care medicine , monoclonal , plasmacytoma , pathology , immunology , antibody , political science , law , monoclonal antibody
Multiple myeloma (MM) is a malignant plasma-cell disease that arises on the basis of a so-called monoclonal gammopathy of undetermined significance (MGUS). The median age at disease onset is over 70. In Germany, there are approximately eight new cases per 100 000 inhabitants per year, or about 6000 new patients nationwide each year.